Price Rebates Will Continue As ‘Fact Of Life’ In Drug Contracting

Pharmacy benefit managers will continue to collect rebates from manufacturers in return for market share even though the practice is being challenged by drug pricing critics, Avalere’s Mendelson predicts.

PharmacyReceipt-Dollars-PillBottles_1200x675

Price rebates will continue to figure prominently in purchasing contracts between biopharmaceutical manufacturers and pharmacy benefit managers despite criticism that the practice creates a lack of pricing transparency and is not suited to high deductible health plans, Avalere Health President Dan Mendelson predicts.

PBMs negotiate rebates (retroactive price discounts) with manufacturers in return for market access. PBMs use them to foster competition and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access